SOX2 expression is highly sensitive for MCC (92%), and is highly specific for MCC compared to other cutaneous carcinomas, as well as 70% specific for MCC compared to other neuroendocrine carcinomas (25, 26). Here, SOX2 is linked to neuroendocrine carcinoma.